An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan

American Journal of Ophthalmology

Volumn 155, Issue 1, 2013, Pages 150-158.e1

  Wu, Wei Chi ^a,d   Kuo, Hsi Kung ^a,d   Yeh, Po Ting ^b   Yang, Chung May ^b   Lai, Chi Chun ^a,d   Chen, San Ni ^c,e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CATARACT; DISEASE COURSE; DISEASE SEVERITY; DIVERGENT STRABISMUS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; TAIWAN; TREATMENT RESPONSE; VITRECTOMY;

EID: 84871246193     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.06.010     Document Type: Article

References (63)

1. T. Alon, I. Hemo, and A. Itin Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity Nat Med 1 10 1995 1024 1028
2. Early Treatment For Retinopathy Of Prematurity Cooperative Group Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial Arch Ophthalmol 121 12 2003 1684 1694
3. M.X. Repka, B. Tung, and W.V. Good Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP) Arch Ophthalmol 124 1 2006 24 30
4. W.S. Gilbert, G.E. Quinn, and V. Dobson Partial retinal detachment at 3 months after threshold retinopathy of prematurity Long-term structural and functional outcome. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group Arch Ophthalmol 114 9 1996 1085 1091
5. W.C. Wu, K.A. Drenser, and M. Lai Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity Retina 28 3 suppl 2008 S75 S80
6. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
7. Z.F. Bashshur, Z.A. Haddad, and A.R. Schakal Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study Am J Ophthalmol 148 1 2009 59 65
8. R.F. Spaide, K. Laud, and H.F. Fine Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 4 2006 383 390
9. R.L. Avery, J. Pearlman, and D.J. Pieramici Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 10 2006 1695.e1 1695.e15
10. J.O. Mason 3rd, P.A. Nixon, and M.F. White Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy Am J Ophthalmol 142 4 2006 685 688
11. R.F. Spaide, and Y.L. Fisher Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 26 3 2006 275 278
12. J.B. Jonas, T. Libondi, B.S. von, and U. Vossmerbaeumer Intravitreal bevacizumab for vitreous haemorrhage Acta Ophthalmol 86 5 2008 585 586
13. J.M. Ruiz-Moreno, J.A. Montero, and F. Lugo Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy Acta Ophthalmol 86 2 2008 231 232
14. M.E. Iliev, D. Domig, and U. Wolf-Schnurrbursch Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma Am J Ophthalmol 142 6 2006 1054 1056
15. G.B. Jaissle, M. Leitritz, and F. Gelisken One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion Graefes Arch Clin Exp Ophthalmol 247 1 2009 27 33
16. F. Prager, S. Michels, and K. Kriechbaum Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion-12-month results of a prospective clinical trial Br J Ophthalmol 93 4 2009 452 456
17. K. Kriechbaum, S. Michels, and F. Prager Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study Br J Ophthalmol 92 4 2008 518 522
18. T. Sato, S. Kusaka, H. Shimojo, and T. Fujikado Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity Ophthalmology 116 11 2009 2165 2169
19. T. Sato, S. Kusaka, H. Shimojo, and T. Fujikado Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity Ophthalmology 116 9 2009 1599 1603
20. H.A. Mintz-Hittner, K.A. Kennedy, and A.Z. Chuang Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 7 2011 603 615
21. W.C. Wu, P.T. Yeh, and S.N. Chen Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan Ophthalmology 118 1 2011 176 183
22. G.A. Lalwani, A.M. Berrocal, and T.G. Murray Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity Retina 28 3 suppl 2008 S13 S18
23. H.A. Mintz-Hittner, and R.R. Kuffel Jr Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II Retina 28 6 2008 831 838
24. H. Quiroz-Mercado, M.A. Martinez-Castellanos, and M.L. Hernandez-Rojas Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity Retina 28 3 suppl 2008 S19 S25
25. S. Kusaka, C. Shima, and K. Wada Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study Br J Ophthalmol 92 11 2008 1450 1455
26. L. Kong, H.A. Mintz-Hittner, and R.L. Penland Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study Arch Ophthalmol 126 8 2008 1161 1163
27. E. Rishi, P. Rishi, D. Ratra, and M. Bhende Off-label use of bevacizumab in retinopathy of prematurity Retina 29 2 2009 284 285
28. A. Travassos, S. Teixeira, and P. Ferreira Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity Ophthalmic Surg Lasers Imaging 38 3 2007 233 237
29. R. Azad, and P. Chandra Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity Indian J Ophthalmol 55 4 2007 319
30. E.J. Chung, J.H. Kim, H.S. Ahn, and H.J. Koh Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity Graefes Arch Clin Exp Ophthalmol 245 11 2007 1727 1730
31. B.C. Harder, B.S. von, J.B. Jonas, and F.C. Schlichtenbrede Intravitreal bevacizumab for retinopathy of prematurity J Ocul Pharmacol Ther 27 6 2011 623 627
32. S. Raizada, K.J. Al, and F.A. Al Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity Middle East Afr J Ophthalmol 18 2 2011 196 197
33. R. Axer-Siegel, M. Snir, and Y. Ron Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity Retina 31 7 2011 1239 1247
34. B. Wutthiworawong, U. Thitiratsanont, and C. Saovaprut Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP) J Med Assoc Thai 94 suppl 3 2011 S15 S21
35. B.T. Chan-Kai, and A.K. Lauer Transconjunctival, sutureless 25-gauge lens sparing vitrectomy for stage 4 retinopathy of prematurity-related retinal detachments Retina 29 6 2009 854 859
36. L.E. Smith Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture Invest Ophthalmol Vis Sci 49 12 2008 5177 5182
37. R. Foroozan, B.P. Connolly, and W.S. Tasman Outcomes after laser therapy for threshold retinopathy of prematurity Ophthalmology 108 9 2001 1644 1646
38. A. Kychenthal, P. Dorta, and X. Katz Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes Retina 26 7 suppl 2006 S11 S15
39. M. O'Keefe, B. Lanigan, and V.W. Long Outcome of zone 1 retinopathy of prematurity Acta Ophthalmol Scand 81 6 2003 614 616
40. B.V. Davitt, V. Dobson, and G.E. Quinn Astigmatism in the Early Treatment for Retinopathy of Prematurity Study: findings to 3 years of age Ophthalmology 116 2 2009 332 339
41. G.E. Quinn, V. Dobson, and B.V. Davitt Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age Ophthalmology 115 6 2008 1058 1064
42. G.E. Quinn, V. Dobson, and R.J. Hardy Visual fields measured with double-arc perimetry in eyes with threshold retinopathy of prematurity from the cryotherapy for retinopathy of prematurity trial The CRYO-Retinopathy of Prematurity Cooperative Group Ophthalmology 103 9 1996 1432 1437
43. D.M. Moshfeghi, and A.M. Berrocal Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice Ophthalmology 118 7 2011 1227 1228
44. M.B. Yang, E.F. Donovan, and J.R. Wagge Race, gender, and clinical risk index for babies (CRIB) score as predictors of severe retinopathy of prematurity J AAPOS 10 3 2006 253 261
45. M. Tadesse, R. Dhanireddy, M. Mittal, and R.D. Higgins Race, Candida sepsis, and retinopathy of prematurity Biol Neonate 81 2 2002 86 90
46. G. Heidary, D. Vanderveen, and L.E. Smith Retinopathy of prematurity: current concepts in molecular pathogenesis Semin Ophthalmol 24 2 2009 77 81
47. K. Lashkari, T. Hirose, and J. Yazdany Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity Am J Pathol 156 4 2000 1337 1344
48. C. Lofqvist, A. Niklasson, and E. Engstrom A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants Pediatr Res 65 5 2009 574 579
49. T. Miyake, O. Sawada, and M. Kakinoki Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes Invest Ophthalmol Vis Sci 51 3 2010 1606 1608
50. W.C. Wu, C.C. Lai, and K.J. Chen Long-term tolerability and serum concentration of bevacizumab (Avastin) when injected in newborn rabbit eyes Invest Ophthalmol Vis Sci 51 7 2010 3701 3708
51. J. Qian, Q. Lu, Y. Tao, and Y.R. Jiang Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy Retina 31 1 2011 161 168
52. T. Sato, K. Wada, and H. Arahori Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity Am J Ophthalmol 153 2 2012 327 333
53. A.L. Hard, and A. Hellstrom On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review Acta Paediatr 100 12 2011 1523 1527
54. J.A. Micieli, M. Surkont, and A.F. Smith A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity Am J Ophthalmol 148 4 2009 536 543
55. J. Sahni, N.V. Subhedar, and D. Clark Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months Br J Ophthalmol 89 2 2005 154 159
56. S.I. Khwarg, H.G. Yu, and Y.S. Yu Change of refraction in premature infants after cryotherapy for retinopathy of prematurity between the age of six months and three years Korean J Ophthalmol 9 2 1995 111 116
57. J.E. White, and M.X. Repka Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome J Pediatr Ophthalmol Strabismus 34 2 1997 83 87
58. F. Laws, D. Laws, and D. Clark Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study Br J Ophthalmol 81 1 1997 12 15
59. I.A. Pearce, F.C. Pennie, L.M. Gannon, A.M. Weindling, and D.I. Clark Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser Br J Ophthalmol 82 11 1998 1254 1259
60. B.P. Connolly, J.A. McNamara, S. Sharma, C.D. Regillo, and W. Tasman A comparison of laser photocoagulation with trans-scleral cryotherapy in the treatment of threshold retinopathy of prematurity Ophthalmology 105 9 1998 1628 1631
61. N. Fallaha, M.J. Lynn, T.M. Aaberg Jr, and S.R. Lambert Clinical outcome of confluent laser photoablation for retinopathy of prematurity J AAPOS 6 2 2002 81 85
62. A. Al-Ghamdi, D.A. Albiani, W.G. Hodge, and W.N. Clarke Myopia and astigmatism in retinopathy of prematurity after treatment with cryotherapy or laser photocoagulation Can J Ophthalmol 39 5 2004 521 525
63. J. Sahni, N.V. Subhedar, and D. Clark Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months Br J Ophthalmol 89 2 2005 154 159